Zoetis (NYSE:ZTS) Price Target Raised to $210.00

Zoetis (NYSE:ZTS) had its target price increased by Piper Sandler from $205.00 to $210.00 in a report issued on Monday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other equities analysts also recently issued research reports about the stock. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. UBS Group cut their price target on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $212.75.

Zoetis Stock Down 3.5%

Shares of NYSE:ZTS opened at $154.77 on Monday. The stock has a market cap of $68.90 billion, a P/E ratio of 28.29, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis has a 1-year low of $139.70 and a 1-year high of $200.33. The firm has a fifty day moving average price of $156.72 and a 200 day moving average price of $165.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS. Sell-side analysts predict that Zoetis will post 6.07 EPS for the current year.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This trade represents a 9.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zoetis

Several hedge funds have recently modified their holdings of ZTS. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. boosted its position in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares during the last quarter. Navigoe LLC acquired a new stake in shares of Zoetis in the fourth quarter worth approximately $30,000. Cornerstone Planning Group LLC boosted its position in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock worth $42,000 after acquiring an additional 120 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.